GlassScriptPhysician profile
Heather J Sarkis
NPI 1023118122
$2,761.18
in general payments reported to CMS, 2019-2025
27 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $685 · 2022: $236 · 2023: $641 · 2024: $555 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $486.92 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $365.22 | 2021-2024 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $197.76 | 2021-2025 | Airsupra, Breztri |
| Pfizer INC. | $185.64 | 2023-2025 | |
| Lilly USA, LLC | $177.05 | 2021-2025 | Mounjaro, Jardiance |
| Amgen INC. | $133.18 | 2021-2025 | Otezla, Repatha, Repatha |
| Xeris Pharmaceuticals, INC. | $132.27 | 2021-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $113.83 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Glaxosmithkline, LLC. | $101.99 | 2021-2023 | Trelegy Ellipta |
| Boston Scientific Corporation | $97.50 | 2021-2025 | Watchman Flx |
| Astellas Pharma US INC | $93.51 | 2023-2024 | Veozah |
| Abbott Laboratories | $76.91 | 2025 | Amplatzer Amulet, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.82 | 2021-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $72.79 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $68.09 | 2021-2024 | Rexulti, Abilify Maintena |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $54.74 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.77 | 2022 | |
| Phathom Pharmaceuticals, INC. | $47.56 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $40.37 | 2024 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $38.70 | 2021 | |
| Merck Sharp & Dohme LLC | $37.00 | 2022-2024 | Vaxneuvance, Gardasil, Capvaxive |
| Horizon Therapeutics Plc | $29.17 | 2021-2023 | Krystexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.75 | 2022 | |
| Biomerieux INC | $18.00 | 2025 | Biofire Spotfire Control Station |
| Tris Pharma INC | $16.57 | 2024 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $14.19 | 2023 | |
| Corcept Therapeutics | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Sarkis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.